KPV peptide legal status
Is KPV FDA approved? It is not. The FDA's review of KPV and its acetate form states that neither is a component of an FDA-approved drug. That answers the approval question. Whether a bulk ingredient satisfies compounding requirements is another question, governed by the applicable law and the exact preparation.
The withdrawn nomination
On the FDA page current as of April 22, 2026, KPV appears in the table for bulk substances nominated but withdrawn. It is not in that page's Category 2 table. The FDA continues to display its safety concerns beside the withdrawn entry.
The page does not give a date when KPV moved between tables. April 22 identifies the page's stated currency, not a published date of reclassification for this substance. Assigning a separate move date would add information that the record does not contain.
Withdrawal means the nomination was taken back. It grants no FDA approval, no clearance for compounding, and no Category 1 placement. A change in a nomination's position cannot be read as evidence that human safety has been established.
What compounding does and does not mean
Compounding involves preparing a medicine to meet a particular need, rather than supplying an approved finished product. The FDA's explanation of compounding describes the role of these preparations and their limits. Compounded preparations do not receive FDA approval through that process.
Section 503A generally concerns preparation for an identified patient on a valid prescription, subject to the law's other conditions. Section 503B concerns registered outsourcing facilities, which may prepare batches without prescriptions for named patients. These are distinct pathways with different requirements, rather than two ways to approve an unapproved drug.
The ingredients must also qualify under the relevant pathway. A consultation and a prescription do not settle whether a particular bulk substance is eligible. The FDA's 503A ingredient discussion explains the separate tests involving official standards, approved-drug components, and the bulks list.
The ingredient record for KPV
In its July 2026 assessment, the FDA found no applicable USP or NF drug-substance monograph for KPV free base or KPV acetate. These monographs are official quality standards. The assessment also states that neither form is a component of an FDA-approved drug and proposes against adding them to the 503A Bulks List.
Those findings need to stay separate from the fact that KPV is discussed online or appears in commercial ingredient records. An ingredient listing does not establish a drug approval. Nor does a different salt name remove the need to identify the precise substance and the legal basis for its use.
The FDA review also describes inconsistent naming as a safety concern. The common name KPV can obscure differences between salts and derivatives. A legal or clinical discussion needs the actual chemical form, rather than relying on a familiar short name alone.
Advisory review and final action
The July 23–24, 2026 advisory meeting concerned substances being considered for the compounding list. FDA staff had proposed against listing KPV. The October 30, 2026 HHS draft records a committee vote in favor of adding KPV despite that staff recommendation; no vote count is published.
An advisory recommendation would not itself change the ingredient list. The FDA describes notice-and-comment rulemaking as the route for changing the list. A staff proposal, committee discussion, nomination withdrawal, and final rule are different events.
The October 2026 draft policy
In a draft policy published October 30, 2026, HHS said it does not intend to take enforcement action against state-licensed pharmacies, federal facilities, and licensed physicians that compound KPV as the only active ingredient for an individual patient's valid prescription. The policy sets conditions on ingredient identity, administration route, sourcing, labeling, and adverse-event reporting.
This is a nonbinding draft, not FDA approval. KPV is still not on FDA's 503A bulks list, and compounded drugs are not FDA-approved. The policy does not cover 503B outsourcing facilities or blends containing KPV.
The comment deadline is November 13, 2026. The draft says this approach would last until a final rule includes or excludes KPV from that list.
Prescribing decisions and personal questions
A licensed clinician can evaluate a person's condition and the evidence for available treatments. That assessment is not performed by this guide. It also cannot replace a pharmacy's obligation to establish that its ingredients and preparation satisfy the governing requirements.
For an access discussion, useful questions include the exact ingredient, the proposed condition, the evidence in humans, and the applicable compounding basis. The FAQ discusses how blends differ from single-ingredient KPV. This page describes the regulatory record for general understanding; it does not provide medical or legal advice or arrange access to any preparation.